Schuetz Audrey N, Ferrell Andrea, Hindler Janet A, Humphries Romney, Bobenchik April M
Department of Laboratory Medicine and Pathology, Mayo Clinic College of Medicine and Science, Rochester, Minnesota, USA.
R&D, BD Life Sciences, Sparks, Maryland, USA.
J Clin Microbiol. 2025 Sep 10;63(9):e0162323. doi: 10.1128/jcm.01623-23. Epub 2025 Aug 7.
The Clinical and Laboratory Standards Institute Subcommittee on Antimicrobial Susceptibility Testing (AST) publishes annual updates to the M100 . This important document contains key information critical to the laboratory's performance of accurate and current AST. This minireview will highlight and provide supporting data for major changes in the M100 32nd and 33rd editions published in February 2022 and March 2023, respectively. New and revised breakpoints for gram-negative and gram-positive organisms are explained. Proper use of the restructured M100 Table 1 guidance for antimicrobial agents to be considered for testing and reporting is outlined. Reporting guidance for multidrug-resistant gram-negative bacilli is discussed. Other topics within this minireview include additional agents to test and report for direct blood disk diffusion of gram-negative bacilli and quality control range changes and troubleshooting. The minireview concludes with other issues under consideration by the AST Subcommittee.
临床和实验室标准协会抗菌药物敏感性试验(AST)小组委员会每年都会发布M100的更新内容。这份重要文件包含了对于实验室准确开展最新AST检测至关重要的关键信息。本综述将重点介绍并提供支持数据,以说明分别于2022年2月和2023年3月发布的M100第32版和第33版中的主要变化。解释了革兰氏阴性菌和革兰氏阳性菌新的和修订后的断点。概述了如何正确使用重新构建的M100表1中关于应考虑进行检测和报告的抗菌药物的指导。讨论了多重耐药革兰氏阴性杆菌的报告指导。本综述中的其他主题包括用于革兰氏阴性杆菌直接血盘扩散检测和报告的其他药物,以及质量控制范围的变化和故障排除。本综述最后介绍了AST小组委员会正在考虑的其他问题。